An Ascending and Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of HKI-272 Administered Orally to Japanese Subjects With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Neratinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 11 May 2012 Company added as trial sponsor and additional lead trial centre identified as reported by ClinicalTrials.gov.
- 11 May 2012 Actual patient number 21 added as reported by ClinicalTrials.gov.
- 12 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.